Novartis (VTX:NOVN) has been given a CHF 92 price target by analysts at Morgan Stanley in a report issued on Friday. The firm presently has a “buy” rating on the stock. Morgan Stanley’s price target would indicate a potential upside of 9.59% from the stock’s previous close.
A number of other equities analysts have also recently issued reports on NOVN. set a CHF 90 price objective on shares of Novartis and gave the company a “buy” rating in a research note on Tuesday, September 19th. Baader Bank set a CHF 90 target price on shares of Novartis and gave the stock a “buy” rating in a report on Monday, October 30th. Berenberg Bank set a CHF 88 target price on shares of Novartis and gave the company a “neutral” rating in a research report on Monday, October 30th. Sanford C. Bernstein set a CHF 97 target price on shares of Novartis and gave the company a “buy” rating in a research report on Thursday, October 26th. Finally, Societe Generale set a CHF 95 target price on shares of Novartis and gave the company a “buy” rating in a research report on Wednesday, October 25th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of CHF 86.37.
Novartis (NOVN) opened at CHF 83.95 on Friday. Novartis has a 12-month low of CHF 67.80 and a 12-month high of CHF 85.40.
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.